Insider · CIK 0001792150

Parsey Merdad

Reports to the SEC for 5 companies · NEWTOWN SQUARE, PA

sec.gov

Transactions

Companies

Filings

CIK

0001792150

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	AVBPArriVent BioPharma, Inc. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+13.6K sh	—	—	13,562
2026-06-16	ARDXARDELYX, INC.A Award	Director	AAward	+26.5K sh	—	—	83,746
2026-06-16	ARDXARDELYX, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+39.7K sh	—	—	39,715
2025-06-18	AVBPArriVent BioPharma, Inc. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+15.5K sh	—	—	15,502
2025-06-18	ARDXARDELYX, INC.A Award	Director	AAward	+15.2K sh	—	—	57,291
2025-04-28	AVBPArriVent BioPharma, Inc. · Stock Option (right to buy)A Award	Director	AAward	+28.3K sh	—	—	28,346
2025-04-28	ARDXARDELYX, INC.A Award	Director	AAward	+42.1K sh	—	—	42,056
2025-04-28	ARDXARDELYX, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+64.5K sh	—	—	64,457
2024-12-10	GILDGILEAD SCIENCES, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+3,820 sh	—	—	84,621
2024-12-10	GILDGILEAD SCIENCES, INC.F Tax Payment	Chief Medical Officer	FTax Payment	−1,771 sh	$92.34	−$164K	82,850
2024-12-10	GILDGILEAD SCIENCES, INC. · Restricted Stock UnitM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−3,820 sh	—	—	36,753
2024-11-27	GILDGILEAD SCIENCES, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+57.3K sh	$57.92	+$3.32M	156,893
2024-11-27	GILDGILEAD SCIENCES, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+88.1K sh	$65.38	+$5.76M	245,012
2024-11-27	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−57.3K sh	$91.79	−$5.26M	187,718
2024-11-27	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−88.1K sh	$92.00	−$8.11M	99,599
2024-11-27	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−5,200 sh	$91.80	−$477K	94,399
2024-11-27	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−3,199 sh	$91.80	−$294K	91,200
2024-11-27	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−10.4K sh	$92.00	−$957K	80,801
2024-11-27	GILDGILEAD SCIENCES, INC. · Non-qualified Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−57.3K sh	—	—	64,376
2024-11-27	GILDGILEAD SCIENCES, INC. · Non-qualified Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−88.1K sh	—	—	196
2024-11-06	GILDGILEAD SCIENCES, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+25K sh	$57.92	+$1.45M	125,189
2024-11-06	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−20.6K sh	$91.50	−$1.88M	104,599
2024-11-06	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−5,000 sh	$91.50	−$458K	99,599
2024-11-06	GILDGILEAD SCIENCES, INC. · Non-qualified Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−25K sh	—	—	121,670
2024-10-01	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−2,000 sh	$83.83	−$168K	100,189
2024-09-12	GILDGILEAD SCIENCES, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+25K sh	$57.92	+$1.45M	123,435
2024-09-12	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−21.2K sh	$84.50	−$1.8M	102,189
2024-09-12	GILDGILEAD SCIENCES, INC. · Non-qualified Stock Option (Right to Buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−25K sh	—	—	146,670
2024-09-10	GILDGILEAD SCIENCES, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+3,821 sh	—	—	100,201
2024-09-10	GILDGILEAD SCIENCES, INC.F Tax Payment	Chief Medical Officer	FTax Payment	−1,766 sh	$81.44	−$144K	98,435
2024-09-10	GILDGILEAD SCIENCES, INC. · Restricted Stock UnitM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−3,821 sh	—	—	40,573
2024-07-01	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−2,000 sh	$68.63	−$137K	96,380
2024-06-10	GILDGILEAD SCIENCES, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+3,820 sh	—	—	100,124
2024-06-10	GILDGILEAD SCIENCES, INC.F Tax Payment	Chief Medical Officer	FTax Payment	−1,744 sh	$65.25	−$114K	98,380
2024-06-10	GILDGILEAD SCIENCES, INC. · Restricted Stock UnitM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−3,820 sh	—	—	44,394
2024-06-05	SGMTSagimet Biosciences Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+51.5K sh	—	—	51,459
2024-04-01	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−2,000 sh	$72.96	−$146K	96,304
2024-03-10	GILDGILEAD SCIENCES, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+3,455 sh	—	—	96,161
2024-03-10	GILDGILEAD SCIENCES, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+6,946 sh	—	—	103,107
2024-03-10	GILDGILEAD SCIENCES, INC.F Tax Payment	Chief Medical Officer	FTax Payment	−4,803 sh	$75.12	−$361K	98,304
2024-03-10	GILDGILEAD SCIENCES, INC. · Restricted Stock UnitM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−3,455 sh	—	—	37,520
2024-03-10	GILDGILEAD SCIENCES, INC. · Restricted Stock UnitM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−6,946 sh	—	—	30,574
2024-03-10	GILDGILEAD SCIENCES, INC. · Non-qualified Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+89.7K sh	—	—	89,660
2024-03-10	GILDGILEAD SCIENCES, INC. · Restricted Stock UnitA Award	Chief Medical Officer	AAward	+17.6K sh	—	—	48,214
2024-02-29	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−8,230 sh	$72.74	−$599K	92,706
2024-02-28	GILDGILEAD SCIENCES, INC.S Sale	Chief Medical Officer	SSale	−2,000 sh	$73.18	−$146K	100,936
2024-01-31	GILDGILEAD SCIENCES, INC.A Award	Chief Medical Officer	AAward	+20.2K sh	—	—	69,701
2024-01-31	GILDGILEAD SCIENCES, INC.A Award	Chief Medical Officer	AAward	+56.6K sh	—	—	126,325
2024-01-31	GILDGILEAD SCIENCES, INC.F Tax Payment	Chief Medical Officer	FTax Payment	−23.7K sh	$78.26	−$1.86M	102,616
2023-12-10	GILDGILEAD SCIENCES, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+2,779 sh	—	—	72,909

Recent filings

Accepted (ET)
Jun 224
Parsey Merdad0001104659-26-076570
SEC(opens sec.gov)
Jun 184
Parsey Merdad0001792150-26-000002
SEC(opens sec.gov)
Jun 234
Parsey Merdad0001628280-25-032728
SEC(opens sec.gov)
Jun 204
Parsey Merdad0001104659-25-061270
SEC(opens sec.gov)
May 144
Parsey Merdad0001628280-25-025641
SEC(opens sec.gov)
Apr 294
Parsey Merdad0001104659-25-041344
SEC(opens sec.gov)
Dec 114
Parsey Merdad0001127602-24-029171
SEC(opens sec.gov)
Nov 294
Parsey Merdad0001127602-24-028232
SEC(opens sec.gov)

Companies

Address

C/O ARRIVENT BIOPHARMA, INC. 18 CAMPUS BOULEVARD SUITE 100

NEWTOWN SQUARE, PA, 19073